S Gail Eckhardt, MD

Associate Dean of Cancer Programs; Director of the LIVESTRONG Cancer Institute; Department Chair; Professor

1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1991 2019

Filter
Article
2019
4 Citations (Scopus)

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J. R., Kopetz, S., Barbee, J., Peterson, J., Freed, B. M., Yacob, B. W., Bagby, S. M., Messersmith, W. A., Slansky, J. E., Pelanda, R. & Eckhardt, S. G., Feb 8 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 37.

Research output: Contribution to journalArticle

Open Access
Heterografts
Immunotherapy
Neoplasms
Triple Negative Breast Neoplasms
Fetal Blood
1 Citation (Scopus)

Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

Sinik, L., Minson, K. A., Tentler, J. J., Carrico, J., Bagby, S. M., Robinson, W. A., Kami, R., Burstyn-Cohen, T., Eckhardt, S. G., Wang, X., Frye, S. V., Shelton Earp, H., DeRyckere, D. & Graham, D. K., Feb 1 2019, In : Molecular cancer therapeutics. 18, 2, p. 278-288 11 p.

Research output: Contribution to journalArticle

Melanoma
Growth
Neoplasms
Therapeutics
Cell Death

Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes

Ma, K. Y., Schonnesen, A. A., Brock, A., Vandenberg, C., Eckhardt, S. G., Liu, Z. & Jiang, N., Feb 21 2019, In : JCI insight. 4, 4

Research output: Contribution to journalArticle

Open Access
RNA Sequence Analysis
Immunotherapy
Genes
Tumor Escape
Cell Line
2018

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

Klauck, P. J., Bagby, S. M., Capasso, A., Bradshaw-Pierce, E. L., Selby, H. M., Spreafico, A., Tentler, J. J., Tan, A. C., Kim, J., Arcaroli, J. J., Purkey, A., Messersmith, W. A., Kuida, K., Eckhardt, S. G. & Pitts, T. M., Feb 5 2018, In : BMC Cancer. 18, 1, 136.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Phosphotransferases
Cell Line
irinotecan
4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido(4,5-b)(1,4)diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide
4 Citations (Scopus)

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Ferrarotto, R., Eckhardt, S. G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L. & Munster, P., Jul 1 2018, In : Annals of Oncology. 29, 7, p. 1561-1568 8 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Diarrhea
Adenoid Cystic Carcinoma
Fatigue
Pharmacokinetics
1 Citation (Scopus)

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

Davis, S. L., Eckhardt, S. G., Diamond, J. R., Messersmith, W. A., Dasari, A., Weekes, C. D., Lieu, C. H., Kane, M., Choon Tan, A., Pitts, T. M. & Leong, S., Dec 1 2018, In : Oncologist. 23, 12, p. 1409-e140

Research output: Contribution to journalArticle

irinotecan
Somatomedin Receptors
Insulin Receptor
Phosphotransferases
Neoplasms
2 Citations (Scopus)

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Diamond, J. R., Eckhardt, S. G., Pitts, T. M., van Bokhoven, A., Aisner, D., Gustafson, D. L., Capasso, A., Sams, S., Kabos, P., Zolman, K., Colvin, T., Elias, A. D., Storniolo, A. M., Schneider, B. P., Gao, D., Tentler, J. J., Borges, V. F. & Miller, K. D., Aug 2 2018, In : Breast Cancer Research. 20, 1, 82.

Research output: Contribution to journalArticle

Aurora Kinases
Triple Negative Breast Neoplasms
Phase II Clinical Trials
Angiogenesis Inhibitors
Microvessels
1 Citation (Scopus)

Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms

Scott, A. J., Arcaroli, J. J., Bagby, S. M., Yahn, R., Huber, K. M., Serkova, N. J., Nguyen, A., Kim, J., Thorburn, A., Vogel, J., Quackenbush, K. S., Capasso, A., Schreiber, A., Blatchford, P., Klauck, P. J., Pitts, T. M., Eckhardt, S. G. & Messersmith, W. A., Oct 1 2018, In : Molecular cancer therapeutics. 17, 10, p. 2112-2122 11 p.

Research output: Contribution to journalArticle

Autophagy
Heterografts
Colorectal Neoplasms
Neoplasms
Growth

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

Capasso, A., Pitts, T. M., Klauck, P. J., Bagby, S. M., Westbrook, L., Kaplan, J., Soleimani, M., Spreafico, A., Tentler, J. J., Diamond, J. R., Arcaroli, J. J., Messersmith, W. A., Eckhardt, S. G. & Leong, S., Oct 1 2018, In : Anti-cancer drugs. 29, 9, p. 827-838 12 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Cell Cycle
Phosphotransferases
Heterografts
Cell Line
2 Citations (Scopus)

Phase IB results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer

Krishnamurthy, A., Dasari, A., Noonan, A. M., Mehnert, J. M., Lockhart, A. C., Leong, S., Capasso, A., Stein, M. N., Sanoff, H. K., Lee, J. J., Hansen, A., Malhotra, U., Rippke, S., Gustafson, D. L., Pitts, T. M., Ellison, K., Davis, S. L., Messersmith, W. A., Eckhardt, S. G. & Lieu, C. H., Sep 15 2018, In : Cancer Research. 78, 18, p. 5398-5407 10 p.

Research output: Contribution to journalArticle

Cyclosporine
Colorectal Neoplasms
Wnt Signaling Pathway
Neoplasms
irinotecan
3 Citations (Scopus)

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular cancer therapeutics. 17, 1, p. 215-221 7 p.

Research output: Contribution to journalArticle

Antibodies, Monoclonal, Humanized
Pharmacokinetics
Neoplasms
Liver
Enzymes
2017
24 Citations (Scopus)

Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors

Ferrarotto, R., Mitani, Y., Diao, L., Guijarro, I., Wang, J., Zweidler-McKay, P., Bell, D., William, W. N., Glisson, B. S., Wick, M. J., Kapoun, A. M., Patnaik, A., Eckhardt, S. G., Munster, P., Faoro, L., Dupont, J., Lee, J. J., Futreal, A., El-Naggar, A. K. & Heymach, J. V., Jan 20 2017, In : Journal of Clinical Oncology. 35, 3, p. 352-360 9 p.

Research output: Contribution to journalArticle

Adenoid Cystic Carcinoma
Neoplasm Metastasis
Bone and Bones
Mutation
Liver
5 Citations (Scopus)

A phase ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced ormetastatic cancers with mutant KRAS

Lieu, C. H., Hidalgo, M., Berlin, J. D., Ko, A. H., Cervantes, A., LoRusso, P., Gerber, D. E., Paul Eder, J., Eckhardt, S. G., Kapp, A. V., Tsuhako, A., McCall, B., Pirzkall, A., Uyei, A. & Tabernero, J., Sep 1 2017, In : Oncologist. 22, 9

Research output: Contribution to journalArticle

Pharmacokinetics
Safety
Epidermal Growth Factor Receptor
Neoplasms
Mitogen-Activated Protein Kinases
3 Citations (Scopus)

Efficacy and molecular mechanisms of differentiated response to the Aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer

Ionkina, A. A., Tentler, J. J., Kim, J., Capasso, A., Pitts, T. M., Ryall, K. A., Howison, R. R., Kabos, P., Sartorius, C. A., Tan, A. C., Eckhardt, S. G. & Diamond, J. R., May 15 2017, In : Frontiers in Oncology. 7, MAY, 94.

Research output: Contribution to journalArticle

Aurora Kinases
Triple Negative Breast Neoplasms
Angiogenesis Inhibitors
Heterografts
Therapeutics
13 Citations (Scopus)

Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors

Oweida, A., Bhatia, S., Hirsch, K., Calame, D., Griego, A., Keysar, S., Pitts, T., Sharma, J., Eckhardt, S. G., Jimeno, A., Wang, X. J., Parkash, G., Califano, J. & Karam, S. D., Mar 1 2017, In : Molecular Carcinogenesis. 56, 3, p. 1189-1196 8 p.

Research output: Contribution to journalArticle

Ephrin-B2
Neoplasms
Therapeutics
Survival
Atlases
1 Citation (Scopus)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model

Scott, A. J., Song, E. K., Bagby, S., Purkey, A., McCarter, M., Gajdos, C., Quackenbush, K. S., Cross, B., Pitts, T. M., Tan, A. C., Eckhardt, S. G., Fenton, H., Arcaroli, J. & Messersmith, W. A., Nov 1 2017, In : PloS one. 12, 11, e0187173.

Research output: Contribution to journalArticle

colorectal neoplasms
Colorectal Neoplasms
explants
animal models
Cells
3 Citations (Scopus)

Normalized synergy predicts that CD8 co-receptor contribution to T cell receptor (TCR) and pMHC binding decreases as TCR affinity increases in human viral-specific T cells

Williams, C. M., Schonnesen, A. A., Zhang, S. Q., Ma, K. Y., He, C., Yamamoto, T., Eckhardt, S. G., Klebanoff, C. A. & Jiang, N., Jul 28 2017, In : Frontiers in immunology. 8, JUL, 894.

Research output: Contribution to journalArticle

T-Cell Antigen Receptor
Major Histocompatibility Complex
T-Lymphocytes
Peptides
CD8 receptor
7 Citations (Scopus)

Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response

Zhang, C., Liu, Z., Bunker, E., Ramirez, A., Lee, S., Peng, Y., Tan, A. C., Eckhardt, S. G., Chapnick, D. A. & Liu, X., Jan 1 2017, In : Journal of Biological Chemistry. 292, 36, p. 15105-15120 16 p.

Research output: Contribution to journalArticle

Electron Transport
Adenosine Triphosphate
Pharmaceutical Preparations
Tumors
Renal Cell Carcinoma
7 Citations (Scopus)

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)

Wong, K. M., Micel, L. N., Selby, H. M., Tan, A. C., Pitts, T. M., Bagby, S. M., Spreafico, A., Klauck, P. J., Blakemore, S. J., Smith, P. F., McDonald, A., Berger, A., Tentler, J. J. & Eckhardt, S. G., Feb 1 2017, In : Investigational New Drugs. 35, 1, p. 11-25 15 p.

Research output: Contribution to journalArticle

Ubiquitination
Enzyme Inhibitors
Protein Transport
Melanoma
Heterografts
3 Citations (Scopus)

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W. M., Quackenbush, K. S., Schreiber, A., Messersmith, W. A., Devaraj, K. M., Blatchford, P., Eckhardt, S. G., Cadogan, E. B., Hughes, G. D., Smith, A., Pitts, T. M. & Arcaroli, J. J., Jan 1 2017, In : Oncotarget. 8, 67, p. 110904-110913 10 p.

Research output: Contribution to journalArticle

irinotecan
Heterografts
Therapeutics
DNA Damage
2016
14 Citations (Scopus)

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

Arcaroli, J. J., Tai, W. M., Mcwilliams, R., Bagby, S., Blatchford, P. J., Varella-Garcia, M., Purkey, A., Quackenbush, K. S., Song, E. K., Pitts, T. M., Gao, D., Lieu, C., Mcmanus, M., Tan, A. C., Zheng, X., Zhang, Q., Ozeck, M., Olson, P., Jiang, Z. Q., Kopetz, S. & 4 others, Jimeno, A., Keysar, S., Eckhardt, S. G. & Messersmith, W. A., Jan 1 2016, In : International Journal of Cancer. 138, 1, p. 195-205 11 p.

Research output: Contribution to journalArticle

Gene Dosage
Colorectal Neoplasms
Biomarkers
Survival
Antibodies
8 Citations (Scopus)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer

Pitts, T. M., Bradshaw-Pierce, E. L., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., Tentler, J. J., McPhillips, K., Klauck, P. J., Capasso, A., Diamond, J. R., Lindsey Davis, S., Tan, A. C., Arcaroli, J. J., Purkey, A., Messersmith, W. A., Ecsedy, J. A. & Eckhardt, S. G., Jan 1 2016, In : Oncotarget. 7, 31, p. 50290-50301 12 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Phosphotransferases
Cell Line
irinotecan
Aurora Kinases
5 Citations (Scopus)

Development and maintenance of a preclinical patient derived tumor xenograft model for the investigation of novel anti-cancer therapies

Bagby, S., Messersmith, W. A., Pitts, T. M., Capasso, A., Varella-Garcia, M., Klauck, P., Kim, J., Tan, A. C., Eckhardt, S. G., Tentler, J. J. & Arcaroli, J., Sep 30 2016, In : Journal of Visualized Experiments. 2016, 115, e54393.

Research output: Contribution to journalArticle

Heterografts
Tumors
Maintenance
Neoplasms
Therapeutics
11 Citations (Scopus)

Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents

Serkova, N. J. & Eckhardt, S. G., Jul 15 2016, In : Frontiers in Oncology. 6, JUL, 152.

Research output: Contribution to journalArticle

Cytotoxins
Cytostatic Agents
Signal Transduction
Positron-Emission Tomography
Tumor Burden
15 Citations (Scopus)

Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors

Macaulay, V. M., Middleton, M. R., Eckhardt, S. G., Rudin, C. M., Juergens, R. A., Gedrich, R., Gogov, S., McCarthy, S., Poondru, S., Stephens, A. W. & Gadgeel, S. M., Jun 15 2016, In : Clinical Cancer Research. 22, 12, p. 2897-2907 11 p.

Research output: Contribution to journalArticle

Insulin Receptor
Epidermal Growth Factor Receptor
Neoplasms
Non-Small Cell Lung Carcinoma
Appointments and Schedules
8 Citations (Scopus)

Phase i trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

Kessler, E. R., Eckhardt, S. G., Pitts, T. M., Bradshaw-Pierce, E. L., O'Byrant, C. L., Messersmith, W. A., Nallapreddy, S., Weekes, C., Spratlin, J., Lieu, C. H., Kane, M. A., Eppers, S., Freas, E. & Leong, S., Apr 1 2016, In : Investigational New Drugs. 34, 2, p. 176-183 8 p.

Research output: Contribution to journalArticle

gemcitabine
Biliary Tract Neoplasms
Pancreatic Neoplasms
Neoplasms
Maximum Tolerated Dose
13 Citations (Scopus)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

Quackenbush, K. S., Bagby, S., Tai, W. M., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., Nguyen, A., Gao, D., Blatchford, P., Capasso, A., Schuller, A. G., Eckhardt, S. G. & Arcaroli, J. J., May 10 2016, In : Oncotarget. 7, 19, p. 28273-28285 13 p.

Research output: Contribution to journalArticle

irinotecan
Tankyrases
Colorectal Neoplasms
Neoplasms
Wnt Signaling Pathway
2015
7 Citations (Scopus)

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer

Ryall, K. A., Kim, J., Klauck, P. J., Shin, J., Yoo, M., Ionkina, A., Pitts, T. M., Tentler, J. J., Diamond, J. R., Eckhardt, S. G., Heasley, L. E., Kang, J. & Tan, A. C., Dec 9 2015, In : BMC Genomics. 16, 12, S2.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Computational Biology
Phosphotransferases
Cell Line
Pharmacology
5 Citations (Scopus)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

Lieu, C. H., Klauck, P. J., Henthorn, P. K., Tentler, J. J., Tan, A. C., Spreafico, A., Selby, H. M., Britt, B. C., Bagby, S. M., Arcaroli, J. J., Messersmith, W. A., Pitts, T. M. & Eckhardt, S. G., Jan 1 2015, In : Oncotarget. 6, 33, p. 34561-34572 12 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Heterografts
Colorectal Neoplasms
Cell Line
Neoplasms
13 Citations (Scopus)

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants

Micel, L. N., Tentler, J. J., Tan, A. C., Selby, H. M., Brunkow, K. L., Robertson, K. M., Davis, S. L., Klauck, P. J., Pitts, T. M., Gangolli, E., Fabrey, R., O'Connell, S. M., Vincent, P. W. & Eckhardt, S. G., Feb 1 2015, In : Molecular cancer therapeutics. 14, 2, p. 317-325 9 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Melanoma
Cell Line
Neoplasms
Tumor Cell Line
10 Citations (Scopus)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models

Lindsey Davis, S., Robertson, K. M., Pitts, T. M., Tentler, J. J., Bradshaw-Pierce, E. L., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., Ecsedy, J. A., Arcaroli, J. J., Messersmith, W. A., Tan, A. C. & Eckhardt, S. G., Jan 1 2015, In : Frontiers in Pharmacology. 6, MAY, 120.

Research output: Contribution to journalArticle

Aurora Kinase A
Mitogen-Activated Protein Kinase Kinases
Colorectal Neoplasms
Drug Combinations
Cell Line
18 Citations (Scopus)

P53 family members regulate phenotypic response to Aurora kinase a inhibition in Triple-negative breast cancer

Tentler, J. J., Ionkina, A. A., Tan, A. C., Newton, T. P., Pitts, T. M., Glogowska, M. J., Kabos, P., Sartorius, C. A., Sullivan, K. D., Espinosa, J. M., Eckhardt, S. G. & Diamond, J. R., May 1 2015, In : Molecular cancer therapeutics. 14, 5, p. 1117-1129 13 p.

Research output: Contribution to journalArticle

Aurora Kinases
Triple Negative Breast Neoplasms
Aurora Kinase A
Apoptosis
Antimitotic Agents
22 Citations (Scopus)

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors

Goldman, J., Eckhardt, S. G., Borad, M. J., Curtis, K. K., Hidalgo, M., Calvo, E., Ryan, D. P., Wirth, L. J., Parikh, A., Partyka, J., Faessel, H., Gangolli, E., Stewart, S., Rosen, L. S. & Bowles, D. W., Mar 1 2015, In : Clinical Cancer Research. 21, 5, p. 1002-1009 8 p.

Research output: Contribution to journalArticle

Neoplasms
Biopsy
Muscle Fatigue
Skin
Maximum Tolerated Dose
24 Citations (Scopus)

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model

Song, E. K., Tai, W. M., Messersmith, W. A., Bagby, S., Purkey, A., Quackenbush, K. S., Pitts, T. M., Wang, G., Blatchford, P., Yahn, R., Kaplan, J., Tan, A. C., Atreya, C. E., Eckhardt, S. G., Kelley, R. K., Venook, A., Kwak, E. L., Ryan, D. & Arcaroli, J. J., Apr 15 2015, In : International Journal of Cancer. 136, 8, p. 1967-1975 9 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Neoplasms
Vascular Endothelial Growth Factor A
Mutation
Heterografts
2014
34 Citations (Scopus)

Association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD clinical trials program

Lieu, C. H., Renfro, L. A., De Gramont, A., Meyers, J. P., Maughan, T. S., Seymour, M. T., Saltz, L., Goldberg, R. M., Sargent, D. J., Eckhardt, S. G. & Eng, C., Sep 20 2014, In : Journal of Clinical Oncology. 32, 27, p. 2975-2982 8 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Clinical Trials
Survival
Disease-Free Survival
Biomarkers
10 Citations (Scopus)

Distress among caregivers of phase I trial participants: A cross-sectional study

Kessler, E. R., Moss, A., Eckhardt, S. G., Laudenslager, M. L., Kilbourn, K., Mauss, I. B., Bowles, D. W., Hecker, S., Fairclough, D. L. & Kutner, J. S., Jan 1 2014, In : Supportive Care in Cancer. 22, 12, p. 3331-3340 10 p.

Research output: Contribution to journalArticle

Caregivers
Cross-Sectional Studies
Clinical Trials, Phase I
Emotions
Patient Selection
22 Citations (Scopus)

Dual pharmacological targeting of the map kinase and pi3k/mtor pathway in preclinical models of colorectal cancer

Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., Tan, A. C., Messersmith, W. A., Eckhardt, S. G. & Leong, S., Nov 17 2014, In : PloS one. 9, 11, e113037.

Research output: Contribution to journalArticle

colorectal neoplasms
Colorectal Neoplasms
phosphotransferases (kinases)
Phosphotransferases
Pharmacology
25 Citations (Scopus)

Phase i study of oral rigosertib (ON 01910.NA), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies

Bowles, D. W., Diamond, J. R., Lam, E. T., Weekes, C. D., Astling, D. P., Anderson, R. T., Leong, S., Gore, L., Varella-Garcia, M., Vogler, B. W., Keysar, S. B., Freas, E., Aisner, D. L., Ren, C., Tan, A. C., Wilhelm, F., Maniar, M., Eckhardt, S. G., Messersmith, W. A. & Jimeno, A., Jan 1 2014, In : Clinical Cancer Research. 20, 6, p. 1656-1665 10 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Maximum Tolerated Dose
Catenins
Pharmacokinetics
Neoplasms
2013
6 Citations (Scopus)

Accelerated approval and breakthrough therapy designation: Oncology drug development on speed?

Yao, J. C., Meric-Bernstam, F., Lee, J. J. & Eckhardt, S. G., Aug 15 2013, In : Clinical Cancer Research. 19, 16, p. 4305-4308 4 p.

Research output: Contribution to journalArticle

Drug Approval
Biotechnology
Pharmaceutical Preparations
Neoplasms
Therapeutics
22 Citations (Scopus)

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

Pitts, T. M., Kulikowski, G. N., Tan, A. C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., Britt, B. C., Bradshaw-Pierce, E. L., Messersmith, W. A., Varella-Garcia, M. & Eckhardt, S. G., Aug 21 2013, In : Frontiers in Pharmacology. 4 MAR, Article 35.

Research output: Contribution to journalArticle

p21-Activated Kinases
Epithelial-Mesenchymal Transition
Colonic Neoplasms
Phenotype
Colorectal Neoplasms
49 Citations (Scopus)

AZD1480: A phase I study of a novel JAK2 inhibitor in solid tumors

Plimack, E. R., LoRusso, P. M., McCoon, P., Tang, W., Krebs, A. D., Curt, G. & Eckhardt, S. G., Jun 1 2013, In : Oncologist. 18, 7, p. 819-820 2 p.

Research output: Contribution to journalArticle

Granulocytes
Neoplasms
Janus Kinase 1
Janus Kinase 2
Withholding Treatment
16 Citations (Scopus)

First-in-human phase i trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies

Yap, T. A., Arkenau, H. T., Camidge, D. R., George, S., Serkova, N. J., Gwyther, S. J., Spratlin, J. L., Lal, R., Spicer, J., Desouza, N. M., Leach, M. O., Chick, J., Poondru, S., Boinpally, R., Gedrich, R., Brock, K., Stephens, A., Eckhardt, S. G., Kaye, S. B., Demetri, G. & 1 others, Scurr, M., Feb 15 2013, In : Clinical Cancer Research. 19, 4, p. 909-919 11 p.

Research output: Contribution to journalArticle

Appointments and Schedules
Maximum Tolerated Dose
Pharmacokinetics
Positron-Emission Tomography
Platelet-Derived Growth Factor Receptors
13 Citations (Scopus)

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma

Diamond, J. R., Salgia, R., Varella-Garcia, M., Kanteti, R., LoRusso, P. M., Clark, J. W., Xu, L. G., Wilner, K., Eckhardt, S. G., Ching, K. A., Lira, M. E., Schoenmakers, E. F. P. M., Christensen, J. G. & Camidge, D. R., Jun 1 2013, In : Journal of Clinical Oncology. 31, 16

Research output: Contribution to journalArticle

Neoplasm Drug Resistance
Proto-Oncogene Proteins c-met
Pyrazines
Triazoles
Kidney Neoplasms
72 Citations (Scopus)

MERTK receptor tyrosine kinase is a therapeutic target in melanoma

Schlegel, J., Sambade, M. J., Sather, S., Moschos, S. J., Tan, A. C., Winges, A., DeRyckere, D., Carson, C. C., Trembath, D. G., Tentler, J. J., Eckhardt, S. G., Kuan, P. F., Hamilton, R. L., Duncan, L. M., Miller, C. R., Nikolaishvili-Feinberg, N., Midkiff, B. R., Liu, J., Zhang, W., Yang, C. & 5 others, Wang, X., Frye, S. V., Earp, H. S., Shields, J. M. & Graham, D. K., May 1 2013, In : Journal of Clinical Investigation. 123, 5, p. 2257-2267 11 p.

Research output: Contribution to journalArticle

Proto-Oncogenes
Receptor Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Melanoma
Therapeutics
37 Citations (Scopus)

Multicenter phase i trial of the mitogen-activated protein kinase 1/2 inhibitor bay 86-9766 in patients with advanced cancer

Weekes, C. D., Von Hoff, D. D., Adjei, A. A., Leffingwell, D. P., Eckhardt, S. G., Gore, L., Lewis, K. D., Weiss, G. J., Ramanathan, R. K., Dy, G. K., Ma, W. W., Sheedy, B., Iverson, C., Miner, J. N., Shen, Z., Yeh, L. T., Dubowy, R. L., Jeffers, M., Rajagopalan, P. & Clendeninn, N. J., Mar 1 2013, In : Clinical Cancer Research. 19, 5, p. 1232-1243 12 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Mitogen-Activated Protein Kinase 1
Extracellular Signal-Regulated MAP Kinases
Pharmacokinetics
Neoplasms
34 Citations (Scopus)

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models

Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., Eckhardt, S. G. & Leong, S., Nov 15 2013, In : Clinical Cancer Research. 19, 22, p. 6219-6229 11 p.

Research output: Contribution to journalArticle

Insulin Receptor
Mitogen-Activated Protein Kinase Kinases
Insulin Resistance
Colorectal Neoplasms
Cell Line
5 Citations (Scopus)

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib

Dy, G. K., Infante, J. R., Eckhardt, S. G., Novello, S., Ma, W. W., Jones, S. F., Huff, A., Wang, Q., Suttle, A. B., Ottesen, L. H., Adjei, A. A. & Burris, H. A., Aug 1 2013, In : Investigational New Drugs. 31, 4, p. 891-899 9 p.

Research output: Contribution to journalArticle

Angiogenesis Inhibitors
Maximum Tolerated Dose
Exanthema
pazopanib
Erlotinib Hydrochloride
30 Citations (Scopus)

Predictive biomarkers of sensitivity to the Aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models

Diamond, J. R., Eckhardt, S. G., Tan, A. C., Newton, T. P., Selby, H. M., Brunkow, K. L., Kachaeva, M. I., Varella-Garcia, M., Pitts, T. M., Bray, M. R., Fletcher, G. C. & Tentler, J. J., Jan 1 2013, In : Clinical Cancer Research. 19, 1, p. 291-303 13 p.

Research output: Contribution to journalArticle

Aurora Kinases
Angiogenesis Inhibitors
Triple Negative Breast Neoplasms
Biomarkers
Breast Neoplasms
48 Citations (Scopus)

Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer

Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., Micel, L. N., Selby, H. M., Newton, T. P., McPhillips, K. L., Gustafson, D. L., DeGregori, J. V., Messersmith, W. A., Winn, R. A. & Eckhardt, S. G., Aug 1 2013, In : Clinical Cancer Research. 19, 15, p. 4149-4162 14 p.

Research output: Contribution to journalArticle

Wnt Signaling Pathway
Mitogen-Activated Protein Kinase Kinases
Cyclosporine
Colorectal Neoplasms
Calcium
89 Citations (Scopus)

Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies

Micel, L. N., Tentler, J. J., Smith, P. G. & Eckhardt, S. G., Mar 20 2013, In : Journal of Clinical Oncology. 31, 9, p. 1231-1238 8 p.

Research output: Contribution to journalArticle

Proteasome Endopeptidase Complex
Ligases
Ubiquitin
Carcinogenesis
Therapeutics